This suggests that GRB7 may be a viable target for immunomodulatory strategies targeted at enhancing the effectiveness of immunotherapy in ovarian cancer patients, in addition to serving as a possible prognostic biomarker for the disease. This evidence concerns the gene GRB7 and ovarian cancer.